Novo Nordisk A/S Ups Outlook, Costs Weigh on Q4

Reuters -- Danish drugmaker Novo Nordisk, which won U.S. approval for its key new Victoza diabetes drug last week, posted forecast-beating quarterly profits helped by growing modern insulin sales.